Advertisement
Singapore markets closed

  • Straits Times Index

    3,307.90
    -6.15 (-0.19%)
     

  • Nikkei

    38,727.93
    -219.00 (-0.56%)
     

  • Hang Seng

    19,220.62
    0.00 (0.00%)
     

  • FTSE 100

    8,416.45
    -7.75 (-0.09%)
     

  • Bitcoin USD

    70,129.41
    -759.91 (-1.07%)
     

  • CMC Crypto 200

    1,525.27
    +36.73 (+2.47%)
     

  • S&P 500

    5,321.41
    +13.28 (+0.25%)
     

  • Dow

    39,872.99
    +66.22 (+0.17%)
     

  • Nasdaq

    16,832.62
    +37.75 (+0.22%)
     

  • Gold

    2,426.00
    +0.10 (+0.00%)
     

  • Crude Oil

    79.06
    -0.20 (-0.25%)
     

  • 10-Yr Bond

    4.4140
    -0.0230 (-0.52%)
     

  • FTSE Bursa Malaysia

    1,622.09
    -5.41 (-0.33%)
     

  • Jakarta Composite Index

    7,186.04
    -7,266.69 (-50.28%)
     

  • PSE Index

    6,633.66
    0.00 (0.00%)
     

Ultimovacs ASA: Invitation to first quarter 2024 results webcast presentation

Ultimovacs ASA
·1-min read
Ultimovacs ASA
Ultimovacs ASA

Oslo, April 30, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, invites to a webcast presentation of its first quarter 2024 results on Tuesday, May 7, 2024.

The presentation can be followed as a live webcast accessed through a link on www.ultimovacs.com at 14:00 CET on Tuesday, May 7, 2024, and is scheduled to conclude at 14:55 CET. The webcast presentation will be available on the Ultimovacs website, and it will be possible to post questions during the presentation through the webcast.

The report and presentation will be available on the company website from 07:00 CET the same day.

ADVERTISEMENT

For further information, please see www.ultimovacs.com or contact:

Carlos de Sousa, CEO
Email: carlos.desousa@ultimovacs.com
Phone: +47 908 92507

Hans Vassgård Eid, CFO
Email: hans.eid@ultimovacs.com
Phone: +47 482 48632

Anne Worsøe, Head of Investor Relations
Email: anne.worsoe@ultimovacs.com
Phone: +47 906 86815